List of Flonase Sensimist Allergy Relief drug patents

Flonase Sensimist Allergy Relief is owned by Glaxosmithkline Cons.

Flonase Sensimist Allergy Relief contains Fluticasone Furoate.

Flonase Sensimist Allergy Relief has a total of 5 drug patents out of which 0 drug patents have expired.

Flonase Sensimist Allergy Relief was authorised for market use on 02 August, 2016.

Flonase Sensimist Allergy Relief is available in spray, metered;nasal dosage forms.

The generics of Flonase Sensimist Allergy Relief are possible to be released after 15 October, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862 GLAXOSMITHKLINE CONS Fluid dispensing device
Nov, 2024

(1 year, 7 months from now)

US8752543 GLAXOSMITHKLINE CONS Fluid dispensing device
Apr, 2026

(3 years from now)

US8062264 GLAXOSMITHKLINE CONS Fluid dispensing device
Apr, 2026

(3 years from now)

US8347879 GLAXOSMITHKLINE CONS Fluid dispensing device
Jul, 2028

(5 years from now)

US8147461 GLAXOSMITHKLINE CONS Fluid dispensing device
Oct, 2028

(5 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 02 August, 2016

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

FLONASE SENSIMIST ALLERGY RELIEF family patents

10

United Kingdom

9

European Union

8

Australia

8

United States

8

China

8

Japan

5

South Africa

5

Brazil

5

Canada

4

Denmark

4

Austria

4

Hong Kong

4

Portugal

4

Cyprus

4

Spain

4

Poland

4

New Zealand

3

Israel

3

Mexico

3

Norway

3

Germany

3

Korea, Republic of

2

Singapore

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in